{"url_path":"/sec/maze/8-k/2026-05-12/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219398-index.html","accession_number":"0001193125-26-219398","cik":"0001842295","ticker":"MAZE","issuer_name":"Maze Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219398-index.html","primary_entity_key":"0001842295","primary_entity_name":"Maze Therapeutics, Inc."},"word_count":154,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 12, 2026, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing."}